American Well (AMWL) 10-Q 3 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 25, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	AMWL
Entity Registrant Name	American Well Corporation
Entity Central Index Key	0001393584
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Security Exchange Name	NYSE
Title of 12(b) Security	Class A common stock,par value of $0.01 per share
Entity File Number	001-39515
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5009396
Entity Address, Address Line One	75 State Street
Entity Address, Address Line Two	26th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	204-3500
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		247,922,856
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		27,390,397
Common Class C [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,555,555

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 112,887	$ 538,546
Investments	394,309
Accounts receivable ($1,700 and $2,597, from related parties and net of allowances of $2,069 and $1,884, respectively)	55,871	58,372
Inventories	8,438	8,737
Deferred contract acquisition costs	1,472	1,394
Prepaid expenses and other current assets	15,275	19,567
Total current assets	588,252	626,616
Restricted cash	795	795
Property and equipment, net	719	1,012
Goodwill	106,707	435,279
Intangible assets, net	135,401	134,980
Operating lease right-of-use asset	12,609	13,509
Deferred contract acquisition costs, net of current portion	3,645	3,394
Other assets	2,199	1,972
Investment in minority owned joint venture (Note 2)	178
Total assets	850,505	1,217,557
Current liabilities:
Accounts payable	7,050	7,236
Accrued expenses and other current liabilities	39,922	54,258
Operating lease liability, current	3,011	3,057
Deferred revenue ($1,232 and $1,665 from related parties, respectively)	65,607	49,505
Total current liabilities	115,590	114,056
Other long-term liabilities	1,611	1,574
Operating lease liability, net of current portion	10,850	11,787
Deferred revenue, net of current portion ($7 and $10 from related parties, respectively)	8,178	6,289
Total liabilities	136,229	133,706
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of March 31, 2023 and as of December 31, 2022
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 247,762,793 and 244,193,727 shares issued and outstanding, respectively; 100,000,000 Class B shares authorized, 27,390,397 shares issued and outstanding; 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of March 31, 2023 and as of December 31, 2022	2,801	2,766
Additional paid-in capital	2,182,627	2,160,108
Accumulated other comprehensive income	(10,588)	(16,969)
Accumulated deficit	(1,479,717)	(1,082,028)
Total American Well Corporation stockholders’ equity	695,123	1,063,877
Non-controlling interest	19,153	19,974
Total stockholders’ equity	714,276	1,083,851
Total liabilities and stockholders’ equity	$ 850,505	$ 1,217,557

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable from related parties	$ 1,700	$ 2,597
Accounts receivable net of allowances	2,069	1,884
Deferred revenue from related parties current	1,232	1,665
Deferred revenue from related parties non current	$ 7	$ 10
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	1,300,000,000
Common Stock, Shares, Issued	280,708,745
Common Stock, Shares, Outstanding	280,708,745
Common Class A [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	247,762,793	244,193,727
Common Stock, Shares, Outstanding	247,762,793	244,193,727
Common Class B [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,390,397	27,390,397
Common Stock, Shares, Outstanding	27,390,397	27,390,397
Common Class C [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	5,555,555	5,555,555
Common Stock, Shares, Outstanding	5,555,555	5,555,555

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
( $988 and $1,215 from related parties, respectively)	$ 64,001	$ 64,232
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets	38,752	36,765
Research and development	25,923	37,481
Sales and marketing	22,726	21,154
General and administrative	36,370	32,716
Depreciation and amortization expense	7,243	6,598
Goodwill Impairment	330,309
Total costs and operating expenses	461,323	134,714
Loss from operations	(397,322)	(70,482)
Interest income and other income (expense), net	940	108
Loss before expense from income taxes and loss from equity method investment	(396,382)	(70,374)
(Expense) Benefit from income taxes	(1,475)	332
Loss from equity method investment	(652)	(211)
Net loss	(398,509)	(70,253)
Net loss attributable to non-controlling interest	(821)	(216)
Net loss attributable to American Well Corporation	$ (397,688)	$ (70,037)
Net loss per share attributable to common stockholders, basic	$ (1.42)	$ (0.26)
Net loss per share attributable to common stockholders, diluted	$ (1.42)	$ (0.26)
Weighted-average common shares outstanding, basic	279,966,645	268,002,110
Weighted-average common shares outstanding, diluted	279,966,645	268,002,110
Net loss	$ (398,509)	$ (70,253)
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on available-for-sale investments	4,319	(1,251)
Foreign currency translation	2,062	(2,951)
Comprehensive loss	(392,128)	(74,455)
Less: Comprehensive loss attributable to non-controlling interest	(821)	(216)
Comprehensive loss attributable to American Well Corporation	$ (391,307)	$ (74,239)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue from Related Parties	$ 988	$ 1,215

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2021	$ 1,260,875	$ 2,620	$ 2,054,275	$ (6,353)	$ (811,284)	$ 1,239,258	$ 21,617
Beginning balance (in shares) at Dec. 31, 2021		261,871,587
Exercise of common stock options	2,465	$ 10	2,455			2,465
Exercise of common stock options, Shares		976,644
Vesting of restricted stock units, including units with a market condition		$ 14	(14)
Vesting of restricted stock units, including units with a market condition ,Shares		1,398,305
Issuance of stock under employee stock purchase plan	1,501	$ 4	1,497			1,501
Issuance of stock under employee stock purchase plan,Shares		425,114
Issuance of common stock related to Conversa earn-out settlement	4,298	$ 10	4,288			4,298
Issuance of common stock related to Conversa earn-out settlement, Shares		1,020,964
Stock-based compensation expense	12,085		12,085			12,085
Capital contributed by selling shareholders of acquired businesses	2,019		2,019			2,019
Currency translation adjustment	(2,951)			(2,951)		(2,951)
Unrealized gains (losses) on available-for-sale securities, net of tax	(1,251)			(1,251)		(1,251)
Net loss	(70,253)				(70,037)	(70,037)	(216)
Ending balance at Mar. 31, 2022	1,208,788	$ 2,658	2,076,605	(10,555)	(881,321)	1,187,387	21,401
Ending balance, Shares at Mar. 31, 2022		265,692,614
Beginning balance at Dec. 31, 2022	1,083,851	$ 2,766	2,160,108	(16,969)	(1,082,028)	1,063,877	19,974
Beginning balance (in shares) at Dec. 31, 2022		277,139,679
Exercise of common stock options	289	$ 1	288			289
Exercise of common stock options, Shares		128,572
Vesting of restricted stock units, including units with a market condition		$ 29	(29)
Vesting of restricted stock units, including units with a market condition ,Shares		2,927,471
Shares repurchased and retired	(1)				(1)	(1)
Shares repurchased and retired,Shares		(316)
Issuance of stock under employee stock purchase plan	1,268	$ 5	1,263			1,268
Issuance of stock under employee stock purchase plan,Shares		513,339
Stock-based compensation expense	20,997		20,997			20,997
Currency translation adjustment	2,062			2,062		2,062
Unrealized gains (losses) on available-for-sale securities, net of tax	4,319			4,319		4,319
Net loss	(398,509)				(397,688)	(397,688)	(821)
Ending balance at Mar. 31, 2023	$ 714,276	$ 2,801	$ 2,182,627	$ (10,588)	$ (1,479,717)	$ 695,123	$ 19,153
Ending balance, Shares at Mar. 31, 2023		280,708,745

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (398,509)	$ (70,253)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill Impairment	330,309
Depreciation and amortization expense	7,242	6,598
Provisions for credit losses	199	(200)
Amortization of deferred contract acquisition costs	476	391
Amortization of deferred contract fulfillment costs	107	133
Noncash compensation costs incurred by selling shareholders		2,025
Stock-based compensation expense	21,008	12,075
Loss on equity method investment	652	211
Deferred income taxes	(13)	(443)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	2,340	4,290
Inventories	299	(495)
Deferred contract acquisition costs	(793)	(501)
Prepaid expenses and other current assets	4,198	(1,838)
Other assets	(210)	(169)
Accounts payable	(247)	(4,601)
Accrued expenses and other current liabilities	(14,159)	(8,446)
Other long-term liabilities		(16)
Deferred revenue	17,953	(952)
Net cash used in operating activities	(29,148)	(62,191)
Cash flows from investing activities:
Purchases of property and equipment	(18)	(68)
Capitalized software development costs	(6,751)
Investment in less than majority owned joint venture	(980)
Purchases of investments	(389,990)	(499,223)
Net cash used in investing activities	(397,739)	(499,291)
Cash flows from financing activities:
Proceeds from exercise of common stock options	289	2,536
Proceeds from employee stock purchase plan	1,268	1,501
Payments for the purchase of treasury stock	(1)
Payment of contingent consideration		(11,790)
Net cash provided by (used in) financing activities	1,556	(7,753)
Effect of exchange rates changes on cash, cash equivalents, and restricted cash	(328)	(247)
Net decrease in cash, cash equivalents, and restricted cash	(425,659)	(569,482)
Cash, cash equivalents, and restricted cash at beginning of period	539,341	747,211
Cash, cash equivalents, and restricted cash at end of period	113,682	177,729
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	112,887	176,934
Restricted cash	795	795
Total cash, cash equivalents, and restricted cash at end of period	113,682	177,729
Supplemental disclosure of cash flow information:
Cash paid (refunded) for income taxes	$ 458	(454)
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock in settlement of earnout		4,298
Receivable related to exercise of common stock options		$ 4

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of Business American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading enterprise software company enabling digital delivery of care for healthcare’s key stakeholders. The Company empowers our clients with the core technology and services necessary to successfully develop and distribute virtual care programs that meet their strategic, operational, financial and clinical objectives under their own brands. Liquidity and Capital Resources The Company expects that its cash, cash equivalents and investments balance as of March 31, 2023 of $ 507,196 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies described in the Company’s Form 10-K for the fiscal year ended December 31, 2022, that have had a material impact on the consolidated financial statements and related notes. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three months ended March 31, 2023 are not necessarily indicative of results for the full 2023 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100 % of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, goodwill, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonainble under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions. Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $ 31,042 and $ 1,944 , respectively, as of March 31, 2023 and $ 31,189 and $ 1,648 , respectively as of December 31, 2022. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 19,746 and $ 18,392 for the three months ended March 31, 2023 and 2022, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended March 31, 2023 and 2022 . Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $ 2,940 as its initial investment for a 49 % interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $ 11,800 in two phases, which is yet to be defined. In April 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. During the three months ended March 31, 2023, the Company made a capital contribution of $ 980 , related to a portion of the phase one capital commitment. For the three months ended March 31, 2023 and 2022, the Company recognized a loss of $ 652 and $ 211 as its proportionate share of the joint venture’s results of operations, respectively. Accordingly, the carrying value of the equity method investment as of March 31, 2023 and December 31, 2022 was $ 178 and $( 150 ), respectively. As the share of losses exceeds the carrying amount of the investment, the carrying amount as of December 31, 2022 is included in the balance of accrued expenses and other current liabilities on the consolidated balance sheet. Concentrations of Credit Risk and Significant Clients Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. The Company has not experienced significant credit losses from its accounts receivable. As of March 31, 2023 two clients accounted for 25 % and 12 % of outstanding accounts receivable, respectively, and as of December 31, 2022 , two clients each accounted for 18 % of outstanding accounts receivable. During the three months ended March 31, 2023 and 2022, sales to one client represented 25 % and 26 % of the Company’s total revenue, respectively. Goodwill We recognize the excess of the purchase price over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized but is tested for impairment annually on November 30 or more frequently if events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. Our goodwill impairment tests are performed at the enterprise level given our single reporting unit. When testing goodwill for impairment, we have the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we elect to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that carrying value exceeds its fair value, we perform a quantitative goodwill impairment test. Under the quantitative goodwill impairment test, if our reporting unit’s carrying amount exceeds its fair value, we will record an impairment charge based on that difference. A charge is reported as impairment of goodwill in the consolidated statements of operations and comprehensive loss. As of March 31, 2023 there was an impairment of goodwill of $ 330,309 as our carrying value exceeded the fair value of our reporting unit. For details associated with the Company's interim goodwill impairment, see Note 7 - Goodwill and Intangible Assets . Fair value determination of our reporting unit requires considerable judgment and is sensitive to changes in underlying assumptions and factors. As a result, there can be no assurance that the estimates and assumptions made for purposes of the quantitative goodwill impairment tests will prove to be an accurate prediction of future results. Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of our reporting unit may include such items as: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. In the event there is a further sustained decline in our stock price, future adverse changes in our projected cash flows, and/or changes in key assumptions, including but not limited to an increase in our discount rate, lower market multiples, lower revenue growth, lower operating margin, and/or a lower terminal growth rate, we may be required conduct additional impairment testing of our goodwill, other intangibles and/or long-lived assets and subsequently record a non-cash impairment charge.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended March 31, 2023 2022 Platform subscription $ 28,695 $ 28,691 Visits 32,537 30,736 Other 2,769 4,805 Total Revenue $ 64,001 $ 64,232 Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from clients. Accounts receivable are presented net of an allowance for credit losses, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in client collection matters, including the aging of unpaid accounts receivable and changes in client financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Changes in the allowance for credit losses were as follows: Three Months Ended March 31, 2023 Year Ended December 31, 2022 Allowance for credit losses, beginning of the $ 1,884 $ 1,809 Provisions 202 803 Write-offs ( 17 ) ( 728 ) Allowance for credit losses, end of the period $ 2,069 $ 1,884 The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the client. The amount of unbilled accounts receivable included within accounts receivable on the consolidated balance sheet was $ 4,252 and $ 3,566 as of March 31, 2023 and December 31, 2022, respectively. Deferred Revenue Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the three months ended March 31, 2023 and 2022, the Company recognized revenue of $ 16,198 and $ 23,147 , respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 and December 31, 2022 were as follows: Three Months Ended March 31, 2023 Year Ended December 31, 2022 Total deferred revenue, beginning of the period $ 55,794 $ 75,896 Additions 47,477 106,330 Recognized ( 29,486 ) ( 126,432 ) Total deferred revenue, end of the period $ 73,785 $ 55,794 Current deferred revenue 65,607 49,505 Non-current deferred revenue 8,178 6,289 Total $ 73,785 $ 55,794 Transaction Price Allocated to Remaining Performance Obligations As of March 31, 2023 and December 31, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $ 194,993 and $ 166,855 , respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years . As it pertains to the March 31, 2023 amount, the Company expects to recognize 47 % of the transaction price in the 12 month period ended March 31, 2024, in its condensed consolidated statement of operations and comprehensive loss with the remainder recognized thereafter.

National Telehealth Network

National Telehealth Network	3 Months Ended
	Mar. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
National Telehealth Network	4. National Telehealth Network In 2012, the Company and an affiliate of Anthem, Inc. (now doing business as Elevance Health) formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significant influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015. On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50 %. The Company also obtained the right to elect the Chairman of NTN, who has the ability to cast the tie-breaking vote in all decisions. Therefore, on January 1, 2016, the Company obtained control over NTN and has the power to direct the activities that most significantly impact NTN’s economic performance. This step-acquisition was accounted for as a business combination and the results of the operations of NTN from January 1, 2016, have been included in the Company’s condensed consolidated financial statements. However, because the Company owns less than 100 % of NTN, the Company recognizes net loss attributable to non-controlling interest in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the ownership interest retained in NTN by the respective non-controlling party. The proportionate share of the (income)/loss attributed to the non-controlling interest amounted to $ 821 and $ 216 for the three months ended March 31, 2023 and 2022, respectively. The carrying value of the non-controlling interest was $ 19,153 and $ 19,974 as of March 31, 2023 and December 31, 2022 , respectively.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: March 31, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 32,514 $ — $ — $ 32,514 U.S government securities — 394,309 — $ 394,309 Total financial assets: $ 32,514 $ 394,309 $ — $ 426,823 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 445,856 $ — $ — $ 445,856 Total financial assets: $ 445,856 $ — $ — $ 445,856 The Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. The Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. During the three months ended March 31, 2023 , there were no transfers between fair value measurement levels.

Investments

Investments	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	6. Investments As of March 31, 2023 and December 31, 2022, the fair value of the Company’s investments by type of security was as follows: March 31, 2023 Amortized Gross Gross Fair Value Assets: U.S government securities $ 389,990 4,319 $ — $ 394,309 $ 389,990 $ 4,319 $ — $ 394,309 December 31, 2022 Amortized Gross Gross Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets Goodwill consisted of the following: Three Months Ended March 31, 2023 Beginning Balance as of January 1 $ 435,279 Goodwill impairment ( 330,309 ) Currency translation adjustments 1,737 Ending Balance $ 106,707 As a result of sustained decreases in the Company's publicly quoted share price and market capitalization during 2023, the Company conducted additional testing of its goodwill, definite-lived intangibles, and other long-lived assets as of March 31, 2023. As a result of this review, the Company did not identify an impairment to its definite-lived intangible assets or other long-lived assets, but the Company did identify indicators of goodwill impairment for the single reporting unit and concluded that a triggering event had occurred which required an interim goodwill impairment assessment. In performing the quantitative assessment of goodwill, our reporting unit’s carrying amount exceeded its fair value. The Company estimated the reporting unit's fair value based on the market capitalization and a related control premium of 30 % (amount paid by a new controlling shareholder for the benefits resulting from synergies and other potential benefits derived from controlling the acquired company). The Company evaluates the implied control premium or discount by comparing it to control premiums or discounts of recent comparable market transactions, as applicable. As a result of the interim quantitative impairment assessment, the Company recorded a $ 330,309 non-deductible, non-cash goodwill impairment charge for the quarter ended March 31, 2023. When considering a hypothetical sensitivity analysis to our goodwill assessment in future periods, should a triggering event be identified, a further 10 % decline in our stock price could result in an impairment charge of approximately $ 85,000 . Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted March 31, 2023 Customer relationships $ 80,341 $ ( 26,958 ) 53,383 7.2 Contractor relationships 535 ( 298 ) 237 5.8 Tradename 14,162 ( 3,637 ) 10,525 4.8 Technology 89,747 ( 34,550 ) 55,197 4.0 Internally developed software 16,905 ( 846 ) 16,059 2.9 $ 201,690 $ ( 66,289 ) $ 135,401 Gross Accumulated Carrying Weighted December 31, 2022 Customer relationships $ 80,168 $ ( 24,919 ) 55,249 7.4 Contractor relationships 535 ( 288 ) 247 6.0 Trade name 14,012 ( 3,050 ) 10,962 5.0 Technology 89,262 ( 30,895 ) 58,367 4.2 Internally developed software 10,155 — 10,155 3.0 $ 194,132 $ ( 59,152 ) $ 134,980 The Company capitalized $ 6,751 of costs during the three months ended March 31, 2023, related to internally developed software to be sold as a service incurred during the application development stage and is amortizing these costs over the expected lives of the related services. Amortization expense related to intangible assets for the three months ended March 31, 2023 and 2022 was $ 6,932 and $ 6,186 , respectively. Estimated future amortization expense of the identified intangible assets as of March 31, 2023, is as follows: 2023 $ 22,739 2024 30,308 2025 30,292 2026 20,883 2027 11,320 Thereafter 19,859 $ 135,401

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: March 31, 2023 December 31, 2022 Employee compensation and benefits $ 15,732 $ 26,192 Professional services 7,218 10,190 Provider services 7,929 8,096 Other 9,043 9,780 Total $ 39,922 $ 54,258

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Undesignated Preferred Stock The Company’s Amended and Restated Certificate of Incorporation authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $ 0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. No shares of preferred stock were issued or outstanding as of March 31, 2023 and December 31, 2022. Common Stock In the three months ended March 31, 2023, no shares of Class B common stock were converted to Class A common stock. As of March 31, 2023, the par value of the Class A, Class B and Class C shares was $ 2,470 , $ 275 , and $ 56 , respectively. Shares Shares Shares Class A 1,000,000,000 247,762,793 247,762,793 Class B 100,000,000 27,390,397 27,390,397 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 280,708,745 280,708,745 As of March 31, 2023 and December 31, 2022, the Company had reserved 82,550,522 and 68,617,245 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units, the vesting of performance-based market condition share awards, and the number of shares remaining available for future grant, respectively. Stock Plans and Stock Options The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified stock options, and restricted stock units to employees, officers, and directors of the Company. In connection with the adoption of the 2020 Plan, the then-remaining shares of common stock reserved for grant or issuance under the 2006 Plan became available for issuance under the 2020 Plan, and no further grants will be made under the 2006 Plan. Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Activity under the Plans is as follows: Number of Weighted Weighted Average Aggregate Outstanding as of January 1, 2023 11,039,551 $ 5.23 5.5 $ 996 Granted — $ — Forfeited ( 173,320 ) $ 5.80 Expired — $ — Exercised ( 128,572 ) $ 2.25 Outstanding as of March 31, 2023 10,737,659 $ 5.24 5.3 $ 207 Vested and expected to vest as of December 31, 2022 10,951,967 $ 5.02 5.5 $ 996 Vested and expected to vest as of March 31, 2023 10,681,404 $ 5.05 5.3 $ 207 Options exercisable as of December 31, 2022 10,417,259 $ 4.97 5.4 $ 996 Options exercisable as of March 31, 2023 10,343,741 $ 5.01 5.2 $ 207 No options were granted in the three months ended March 31, 2023 and 2022. Restricted Stock Units Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of January 1, 2023 19,316,459 $ 10.78 Granted 9,675,841 2.76 Vested ( 2,781,161 ) 7.17 Forfeited ( 511,008 ) 4.86 Unvested as of March 31, 2023 25,700,131 $ 8.27 The total grant date fair value of RSU’s granted for the three months ended March 31, 2023 was $ 26,712 . Restricted stock units vest over the service period of one to four years . The aggregate intrinsic value of restricted stock units vested for the three months ended March 31, 2023 and 2022 was $ 7,693 and $ 6,598 , respectively. Restricted Stock Units with a Market Condition In the three months ended March 31, 2023 , the Company granted performance-based market condition share awards to certain members of the Company’s management team (excluding the co-CEOs), which entitle these employees with the right to receive shares of common stock, upon achievement of certain stock price milestones measured over a rolling thirty day trading-period, subject to the satisfaction of the applicable service vesting conditions. These performance-based market condition share awards consist of three tranches with three separate specified award values t hat become payable upon the achievement of certain stock price milestones, which can result in a vesting range of up to 2,654,598 shares. These performance-based market condition share awards have a performance period of three years . As of March 31, 2023, 146,310 of the performance-based market condition share awards granted in the prior year have satisfied both the applicable market capitalization milestones and the service vesting conditions. Shares Weighted Average Unvested as of January 1, 2023 25,602,405 $ 2.30 Granted 2,654,598 2.19 Vested ( 146,310 ) 3.24 Cancelled/Forfeited — — Unvested as of March 31, 2023 28,110,693 $ 2.28 The total grant-date fair value of performance-based market condition share awards granted during the three months ended March 31, 2023 and 2022 was $ 5,805 and $ 24,978 , respectively. The weighted average estimated fair value of the performance-based market condition share awards granted during the three months ended March 31, 2023 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions: Three Months Ended March 31, 2023 Risk-free rate 4.61 % Term to end of performance period (yrs) 3 years Valuation date stock price $ 2.76 Expected volatility 70 % Expected dividend yield 0 % 2020 Employee Stock Purchase Plan During the three months ended March 31, 2022 , the Company had issued 425,114 shares under the ESPP. During the three months ended March 31, 2023, the Company issued 513,339 shares under the ESPP. As of March 31, 2023 7,634,642 shares remained available for issuance. Stock-Based Compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended March 31, 2023 2022 Cost of revenues $ 398 $ 335 Research and development 2,801 2,182 Selling and marketing 1,986 1,795 General and administrative 15,812 7,773 Total $ 20,997 $ 12,085 As of March 31, 2023, the unrecognized stock-based compensation expense related to unvested common stock-based awards was $ 112,729 , which is expected to be recognized over a weighted-average period of 2.7 years.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Indemnification The Company’s arrangements generally include certain provisions for indemnifying clients against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies clients against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the client. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through March 31, 2023 and December 31, 2022 , there have been no claims under any indemnification provisions. Litigation From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. As of March 31, 2023 and December 31, 2022 , the Company did no t have any pending claims, charges or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes As a result of the Company’s history of net operating losses (“NOL”), the Company continues to maintain a full valuation allowance against its domestic net deferred tax assets. For the three months ended March 31, 2023, the Company recognized an income tax expense of $ 1,475 , primarily due to state and foreign income tax expense. During the three months ended March 31, 2022 , the Company recorded income tax benefit of $ 332 , primarily due to foreign entities generated losses for the quarter.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	12. Related-Party Transactions Cleveland Clinic Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of March 31, 2023 and December 31, 2022, the Company held total deferred revenue of $ 308 and $ 355 , respectively from contracts with this client. As of March 31, 2023 and December 31, 2022, amounts due from Cleveland Clinic were $ 98 and $ 995 , respectively. During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $ 599 and $ 760 , respectively, from contracts with this client. CCAW, JV LLC CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a minority owned interest in. During the year ended December 31, 2020, the Company made an initial investment in CCAW, JV LLC of $ 2,940 for its less than 50 % interest in the joint venture. During the three months ended March 31, 2023 the Company made a capital contribution of $ 980 related to a portion of the phase one capital commitment. During the three months ended March 31, 2023 and 2022 the Company recognized revenue of $ 389 and $ 455 from contracts with this client, respectively. As of March 31, 2023 and December 31, 2022, the Company held total deferred revenue of $ 931 and $ 1,320 , respectively, from contracts with this client. As of March 31, 2023 and December 31, 2022, amounts due from CCAW, JV LLC were $ 1,602 and $ 1,602 .

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share	13. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended March 31, 2023 2022 Numerator: Net loss $ ( 398,509 ) $ ( 70,253 ) Net loss attributable to non-controlling interest ( 821 ) ( 216 ) Net loss attributable to American Well Corporation $ ( 397,688 ) $ ( 70,037 ) Denominator: Weighted-average common shares outstanding 279,966,645 268,002,110 Net loss per share attributable to common $ ( 1.42 ) $ ( 0.26 ) The Company’s potential dilutive securities, which include stock options, unvested restricted stock units and unvested performance market-based stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2023 2022 Unvested restricted stock units 24,623,215 15,008,289 Unvested performance market-based stock units 28,110,693 9,545,814 Options to purchase shares of common stock 10,737,659 14,686,475 63,471,567 39,240,578

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three months ended March 31, 2023 are not necessarily indicative of results for the full 2023 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting currency is the U.S. dollar. The Company determines the functional currency of each subsidiary based on the currency of the primary economic environment in which each subsidiary operates. Items included in the financial statements of such subsidiaries are measured using that functional currency. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100 % of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, goodwill, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonainble under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions.
Segment Information	Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $ 31,042 and $ 1,944 , respectively, as of March 31, 2023 and $ 31,189 and $ 1,648 , respectively as of December 31, 2022. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $ 19,746 and $ 18,392 for the three months ended March 31, 2023 and 2022, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended March 31, 2023 and 2022 .
Investment in Minority Owned Joint Venture	Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via digital care delivery. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $ 2,940 as its initial investment for a 49 % interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $ 11,800 in two phases, which is yet to be defined. In April 2022 the Company made a capital contribution of $ 1,960 related to a portion of the phase one capital commitment. During the three months ended March 31, 2023, the Company made a capital contribution of $ 980 , related to a portion of the phase one capital commitment. For the three months ended March 31, 2023 and 2022, the Company recognized a loss of $ 652 and $ 211 as its proportionate share of the joint venture’s results of operations, respectively. Accordingly, the carrying value of the equity method investment as of March 31, 2023 and December 31, 2022 was $ 178 and $( 150 ), respectively. As the share of losses exceeds the carrying amount of the investment, the carrying amount as of December 31, 2022 is included in the balance of accrued expenses and other current liabilities on the consolidated balance sheet.
Concentrations of Credit Risk and Significant Clients	Concentrations of Credit Risk and Significant Clients Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its clients to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with clients. The Company has not experienced significant credit losses from its accounts receivable. As of March 31, 2023 two clients accounted for 25 % and 12 % of outstanding accounts receivable, respectively, and as of December 31, 2022 , two clients each accounted for 18 % of outstanding accounts receivable. During the three months ended March 31, 2023 and 2022, sales to one client represented 25 % and 26 % of the Company’s total revenue, respectively.
Goodwill	Goodwill We recognize the excess of the purchase price over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized but is tested for impairment annually on November 30 or more frequently if events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. These events include: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. Our goodwill impairment tests are performed at the enterprise level given our single reporting unit. When testing goodwill for impairment, we have the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we elect to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that carrying value exceeds its fair value, we perform a quantitative goodwill impairment test. Under the quantitative goodwill impairment test, if our reporting unit’s carrying amount exceeds its fair value, we will record an impairment charge based on that difference. A charge is reported as impairment of goodwill in the consolidated statements of operations and comprehensive loss. As of March 31, 2023 there was an impairment of goodwill of $ 330,309 as our carrying value exceeded the fair value of our reporting unit. For details associated with the Company's interim goodwill impairment, see Note 7 - Goodwill and Intangible Assets . Fair value determination of our reporting unit requires considerable judgment and is sensitive to changes in underlying assumptions and factors. As a result, there can be no assurance that the estimates and assumptions made for purposes of the quantitative goodwill impairment tests will prove to be an accurate prediction of future results. Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of our reporting unit may include such items as: (i) severe adverse industry or economic trends; (ii) significant company-specific actions, including exiting an activity in conjunction with restructuring of operations; (iii) current, historical or projected deterioration of our financial performance; or (iv) a sustained decrease in our market capitalization, as indicated by the Company’s publicly quoted share price, below our net book value. In the event there is a further sustained decline in our stock price, future adverse changes in our projected cash flows, and/or changes in key assumptions, including but not limited to an increase in our discount rate, lower market multiples, lower revenue growth, lower operating margin, and/or a lower terminal growth rate, we may be required conduct additional impairment testing of our goodwill, other intangibles and/or long-lived assets and subsequently record a non-cash impairment charge.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended March 31, 2023 2022 Platform subscription $ 28,695 $ 28,691 Visits 32,537 30,736 Other 2,769 4,805 Total Revenue $ 64,001 $ 64,232
Summary of Changes in the Allowance for Credit Losses	Changes in the allowance for credit losses were as follows: Three Months Ended March 31, 2023 Year Ended December 31, 2022 Allowance for credit losses, beginning of the $ 1,884 $ 1,809 Provisions 202 803 Write-offs ( 17 ) ( 728 ) Allowance for credit losses, end of the period $ 2,069 $ 1,884
Summary of Significant Changes in the Company's Deferred Revenue	Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 and December 31, 2022 were as follows: Three Months Ended March 31, 2023 Year Ended December 31, 2022 Total deferred revenue, beginning of the period $ 55,794 $ 75,896 Additions 47,477 106,330 Recognized ( 29,486 ) ( 126,432 ) Total deferred revenue, end of the period $ 73,785 $ 55,794 Current deferred revenue 65,607 49,505 Non-current deferred revenue 8,178 6,289 Total $ 73,785 $ 55,794

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: March 31, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 32,514 $ — $ — $ 32,514 U.S government securities — 394,309 — $ 394,309 Total financial assets: $ 32,514 $ 394,309 $ — $ 426,823 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 445,856 $ — $ — $ 445,856 Total financial assets: $ 445,856 $ — $ — $ 445,856

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Debt securities, available-for-sale	As of March 31, 2023 and December 31, 2022, the fair value of the Company’s investments by type of security was as follows: March 31, 2023 Amortized Gross Gross Fair Value Assets: U.S government securities $ 389,990 4,319 $ — $ 394,309 $ 389,990 $ 4,319 $ — $ 394,309 December 31, 2022 Amortized Gross Gross Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill consisted of the following: Three Months Ended March 31, 2023 Beginning Balance as of January 1 $ 435,279 Goodwill impairment ( 330,309 ) Currency translation adjustments 1,737 Ending Balance $ 106,707
Schedule of Finite-Lived Intangible Assets	Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted March 31, 2023 Customer relationships $ 80,341 $ ( 26,958 ) 53,383 7.2 Contractor relationships 535 ( 298 ) 237 5.8 Tradename 14,162 ( 3,637 ) 10,525 4.8 Technology 89,747 ( 34,550 ) 55,197 4.0 Internally developed software 16,905 ( 846 ) 16,059 2.9 $ 201,690 $ ( 66,289 ) $ 135,401 Gross Accumulated Carrying Weighted December 31, 2022 Customer relationships $ 80,168 $ ( 24,919 ) 55,249 7.4 Contractor relationships 535 ( 288 ) 247 6.0 Trade name 14,012 ( 3,050 ) 10,962 5.0 Technology 89,262 ( 30,895 ) 58,367 4.2 Internally developed software 10,155 — 10,155 3.0 $ 194,132 $ ( 59,152 ) $ 134,980
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future amortization expense of the identified intangible assets as of March 31, 2023, is as follows: 2023 $ 22,739 2024 30,308 2025 30,292 2026 20,883 2027 11,320 Thereafter 19,859 $ 135,401

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: March 31, 2023 December 31, 2022 Employee compensation and benefits $ 15,732 $ 26,192 Professional services 7,218 10,190 Provider services 7,929 8,096 Other 9,043 9,780 Total $ 39,922 $ 54,258

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of Common Stock	As of March 31, 2023, the par value of the Class A, Class B and Class C shares was $ 2,470 , $ 275 , and $ 56 , respectively. Shares Shares Shares Class A 1,000,000,000 247,762,793 247,762,793 Class B 100,000,000 27,390,397 27,390,397 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 280,708,745 280,708,745
Activity under Plans	Activity under the Plans is as follows: Number of Weighted Weighted Average Aggregate Outstanding as of January 1, 2023 11,039,551 $ 5.23 5.5 $ 996 Granted — $ — Forfeited ( 173,320 ) $ 5.80 Expired — $ — Exercised ( 128,572 ) $ 2.25 Outstanding as of March 31, 2023 10,737,659 $ 5.24 5.3 $ 207 Vested and expected to vest as of December 31, 2022 10,951,967 $ 5.02 5.5 $ 996 Vested and expected to vest as of March 31, 2023 10,681,404 $ 5.05 5.3 $ 207 Options exercisable as of December 31, 2022 10,417,259 $ 4.97 5.4 $ 996 Options exercisable as of March 31, 2023 10,343,741 $ 5.01 5.2 $ 207
Summary of Unvested Restricted Stock Unit Activity	Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of January 1, 2023 19,316,459 $ 10.78 Granted 9,675,841 2.76 Vested ( 2,781,161 ) 7.17 Forfeited ( 511,008 ) 4.86 Unvested as of March 31, 2023 25,700,131 $ 8.27
Summary of Performance-based Market Condition Share Awards	Shares Weighted Average Unvested as of January 1, 2023 25,602,405 $ 2.30 Granted 2,654,598 2.19 Vested ( 146,310 ) 3.24 Cancelled/Forfeited — — Unvested as of March 31, 2023 28,110,693 $ 2.28
Schedule of Weighted Average Assumptions used to Determine Estimated Fair Value of Performance-based Market Condition Share Awards Granted	The weighted average estimated fair value of the performance-based market condition share awards granted during the three months ended March 31, 2023 was determined using a Monte-Carlo valuation simulation, with the following most significant weighted-average assumptions: Three Months Ended March 31, 2023 Risk-free rate 4.61 % Term to end of performance period (yrs) 3 years Valuation date stock price $ 2.76 Expected volatility 70 % Expected dividend yield 0 %
Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended March 31, 2023 2022 Cost of revenues $ 398 $ 335 Research and development 2,801 2,182 Selling and marketing 1,986 1,795 General and administrative 15,812 7,773 Total $ 20,997 $ 12,085

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended March 31, 2023 2022 Numerator: Net loss $ ( 398,509 ) $ ( 70,253 ) Net loss attributable to non-controlling interest ( 821 ) ( 216 ) Net loss attributable to American Well Corporation $ ( 397,688 ) $ ( 70,037 ) Denominator: Weighted-average common shares outstanding 279,966,645 268,002,110 Net loss per share attributable to common $ ( 1.42 ) $ ( 0.26 )
Summary of Antidilutive Securities Excluded From Computation of Net Loss Per Share	The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2023 2022 Unvested restricted stock units 24,623,215 15,008,289 Unvested performance market-based stock units 28,110,693 9,545,814 Options to purchase shares of common stock 10,737,659 14,686,475 63,471,567 39,240,578

Organization and Description _2

Organization and Description of Business - Additional Information (Detail) $ in Thousands	Mar. 31, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, cash equivalents and investments	$ 507,196

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands		3 Months Ended		12 Months Ended
	Apr. 13, 2022 USD ($)	Mar. 31, 2023 USD ($) Segment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of reportable segment | Segment		1
Number of operating segment | Segment		1
Total assets		$ 850,505		$ 1,217,557
Total liabilities		136,229		$ 133,706
Payment to acquire interest in joint venture		980
Share of the net profit loss in the operations of joint venture		652	$ 211
Impairment of goodwill		$ 330,309
Customer Concentration Risk | Accounts Receivable [Member] | Related Party Client One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		25%		18%
Customer Concentration Risk | Accounts Receivable [Member] | Related Party Client Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		12%		18%
Customer Concentration Risk | Revenue Benchmark [Member] | Related Party Client One [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue		25%	26%
Variable Interest Entity, Primary Beneficiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Total assets		$ 31,042		$ 31,189
Total liabilities		1,944		1,648
Total revenue		19,746	$ 18,392
Variable Interest Entity, Primary Beneficiary [Member] | CCACV JV LLC [Member]
Summary Of Significant Accounting Policies [Line Items]
Payment to acquire interest in joint venture					$ 2,940
Percentage of ownership interest in joint venture					49%
Estimated additional total capital contributions necessary					$ 11,800
Additional capital contribution related to portion of phase one capital commitment	$ 1,960	980
Share of the net profit loss in the operations of joint venture		652	$ 211
Equity method investment carrying value		$ 178		$ (150)
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of economic or ownership interest in consolidated entities		100%

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total Revenue	$ 64,001	$ 64,232
Platform Subscription [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	28,695	28,691
Visits [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	32,537	30,736
Others [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	$ 2,769	$ 4,805

Revenue - Summary of Changes in

Revenue - Summary of Changes in the Allowance for Credit Losses (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Allowance for credit losses, beginning of the period	$ 1,884	$ 1,809
Provisions	202	803
Write-offs	(17)	(728)
Allowance for credit losses, end of the period	$ 2,069	$ 1,884

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue From Contract With Customer Line Items [Line Items]
Contract liability revenue recognized	$ 16,198	$ 23,147
Transaction price allocated to remaining performance obligations	$ 194,993		$ 166,855
Performance obligation percentage of transaction price to recognized in the next twelve months	47%
Accounts Receivable [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled receivables current	$ 4,252		$ 3,566

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer Asset and Liability (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Total deferred revenue, beginning of the period	$ 55,794	$ 75,896
Additions	47,477	106,330
Recognized	(29,486)	(126,432)
Total deferred revenue, end of the period	73,785	55,794
Current deferred revenue	65,607	49,505
Non-current deferred revenue	8,178	6,289
Total	$ 73,785	$ 55,794

Revenue - Additional Informat_2

Revenue - Additional Information (Detail1)	Mar. 31, 2023	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction	3 years

National Telehealth Network - A

National Telehealth Network - Additional Information (Detail) - NTN [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jan. 01, 2016
Schedule of Equity Method Investments [Line Items]
Loss from equity method investments	$ 821	$ 216
Noncontrolling Interest [Member]
Schedule of Equity Method Investments [Line Items]
Non controlling interest carrying value	$ 19,153		$ 19,974
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				50%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				100%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 426,823	$ 445,856
Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	32,514	445,856
U.S Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	394,309
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	32,514	445,856
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	32,514	$ 445,856
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	394,309
Fair Value, Inputs, Level 2 [Member] | U.S Government Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial assets	$ 394,309

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer from level one to level two fair value assets	$ 0
Transfer from level one to level three fair value assets	0
Transfer from level two to level one fair value assets	0
Transfer from level three to level one fair value assets	$ 0

Investments - Debt Securities,

Investments - Debt Securities, Available-For-Sale (Detail) $ in Thousands	Mar. 31, 2023 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 389,990
Gross Unrealized Gains	4,319
Fair Value	394,309
U.S government securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	389,990
Gross Unrealized Gains	4,319
Fair Value	$ 394,309

Business Combinations - Schedul

Business Combinations - Schedule of Identifiable Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Allocation of consideration transferred:
Goodwill	$ 106,707	$ 435,279

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance as of January 1	$ 435,279
Goodwill Impairment	(330,309)
Currency translation adjustments	1,737
Ending Balance	$ 106,707

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of finite lived Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 201,690	$ 194,132
Accumulated Amortization	(66,289)	(59,152)
Carrying Value	135,401	134,980
Customer relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	80,341	80,168
Accumulated Amortization	(26,958)	(24,919)
Carrying Value	$ 53,383	$ 55,249
Weighted Average Remaining Life	7 years 2 months 12 days	7 years 4 months 24 days
Contractor relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 535	$ 535
Accumulated Amortization	(298)	(288)
Carrying Value	$ 237	$ 247
Weighted Average Remaining Life	5 years 9 months 18 days	6 years
Trade name [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 14,162	$ 14,012
Accumulated Amortization	(3,637)	(3,050)
Carrying Value	$ 10,525	$ 10,962
Weighted Average Remaining Life	4 years 9 months 18 days	5 years
Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 89,747	$ 89,262
Accumulated Amortization	(34,550)	(30,895)
Carrying Value	$ 55,197	$ 58,367
Weighted Average Remaining Life	4 years	4 years 2 months 12 days
Internally developed software [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 16,905	$ 10,155
Accumulated Amortization	(846)
Carrying Value	$ 16,059	$ 10,155
Weighted Average Remaining Life	2 years 10 months 24 days	3 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Assumption in fair value of calculation percentage	30%
Goodwill Impairment	$ 330,309
Decline in our stock price percentage	10%
Goodwill impairment charge if decline in stock price	$ 85,000
Capitalized cost related to internally developed software	6,751
Amortization of intangible assets	$ 6,932	$ 6,186

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 22,739
2024	30,308
2025	30,292
2026	20,883
2027	11,320
Thereafter	19,859
Carrying Value	$ 135,401	$ 134,980

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 15,732	$ 26,192
Professional services	7,218	10,190
Provider services	7,929	8,096
Other	9,043	9,780
Total	$ 39,922	$ 54,258

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) Tranche $ / shares shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized	100,000,000		100,000,000
Preferred stock per share | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock authorized	1,300,000,000
Common stock reserve for issuance	82,550,522		68,617,245
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock granted | $	$ 26,712
Aggregate intrinsic value of restricted stock units vested | $	$ 7,693	$ 6,598
Restricted Stock [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vest over the service period	1 year
Restricted Stock [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vest over the service period	4 years
Performance-based Market Condition Share Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of stock granted | $	$ 5,805	$ 24,978
Performance based market condition share awards granted | $	$ 146,310
Performance period	3 years
Number of Unvested shares	28,110,693		25,602,405
Shares, granted	2,654,598
Performance-based Market Condition Share Awards [Member] | Management [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Trading period	30 days
Number of tranches | Tranche	3
Performance-based Market Condition Share Awards [Member] | Maximum [Member] | Management [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Unvested shares	2,654,598
2020 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, granted	0	0
2020 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, issued under ESPP	513,339	425,114
Shares available for issuance	7,634,642
Equity Award Plan [Member] | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation | $	$ 112,729
Weighted-average period	2 years 8 months 12 days
Common Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	1,000,000,000		1,000,000,000
Common stock per share | $ / shares	$ 0.01		$ 0.01
Common stock per share | $ / shares	$ 2,470
Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	100,000,000		100,000,000
Common stock per share | $ / shares	$ 0.01		$ 0.01
Number of shares converted	0
Common stock per share | $ / shares	$ 275
Common Class C [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	200,000,000		200,000,000
Common stock per share | $ / shares	$ 0.01		$ 0.01
Common stock per share | $ / shares	$ 56

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock (Detail) - shares	Mar. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Shares Authorized	1,300,000,000
Shares Issued	280,708,745
Shares Outstanding	280,708,745
Class A [Member]
Class of Stock [Line Items]
Shares Authorized	1,000,000,000	1,000,000,000
Shares Issued	247,762,793	244,193,727
Shares Outstanding	247,762,793	244,193,727
Class B [Member]
Class of Stock [Line Items]
Shares Authorized	100,000,000	100,000,000
Shares Issued	27,390,397	27,390,397
Shares Outstanding	27,390,397	27,390,397
Class C [Member]
Class of Stock [Line Items]
Shares Authorized	200,000,000	200,000,000
Shares Issued	5,555,555	5,555,555
Shares Outstanding	5,555,555	5,555,555

Stockholders' Equity - Activity

Stockholders' Equity - Activity under Plans (Detail) - 2020 Equity Incentive Plan [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding, beginning of period	11,039,551
Number of Shares, Forfeited	(173,320)
Number of Shares, Exercised	(128,572)
Number of Shares, Outstanding, end of period	10,737,659	11,039,551
Number of Shares, Vested and expected to vest	10,681,404	10,951,967
Number of Shares, Options exercisable	10,343,741	10,417,259
Number of Shares, Outstanding, Weighted Average Exercise Price, beginning of period	$ 5.23
Number of Shares, Forfeited, Weighted Average Exercise Price	5.80
Number of Shares, Exercised, Weighted Average Exercise Price	2.25
Number of Shares, Outstanding, Weighted Average Exercise Price, end of period	5.24	$ 5.23
Number of Shares,Vested and expected to vest, Weighted Average Exercise Price, end of period	5.05	5.02
Number of Shares, Options exercisable, Weighted Average Exercise Price, end of period	$ 5.01	$ 4.97
Number of Shares, Outstanding, Weighted Average Remaining Contractual Term (years)	5 years 3 months 18 days	5 years 6 months
Number of Shares, Vested and expected to vest, Weighted Average Remaining Contractual Term (years)	5 years 3 months 18 days	5 years 6 months
Number of Shares, Options exercisable, Weighted Average Remaining Contractual Term (years)	5 years 2 months 12 days	5 years 4 months 24 days
Number of Shares, Outstanding, Aggregate Intrinsic Value	$ 207	$ 996
Number of Shares, Vested and expected to vest, Aggregate Intrinsic Value	207	996
Number of Shares, Options exercisable, Aggregate Intrinsic Value	$ 207	$ 996

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Unvested Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Class of Stock [Line Items]
Unvested as of January 1, 2023 | shares	19,316,459
Shares, Granted | shares	9,675,841
Shares, Vested | shares	(2,781,161)
Shares, Forfeited | shares	(511,008)
Unvested as of March 31, 2023 | shares	25,700,131
Weighted Average Grant Date Fair Value, Unvested as of January 1, 2023 | $ / shares	$ 10.78
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.76
Weighted Average Grant Date Fair Value, Vested | $ / shares	7.17
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	4.86
Weighted Average Grant Date Fair Value, Unvested as of March 31, 2023 | $ / shares	$ 8.27

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Performance-based Market Condition Share Awards (Detail) - Performance-based Market Condition Share Awards [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Class of Stock [Line Items]
Unvested as of January 1, 2023 | shares	25,602,405
Shares, Granted | shares	2,654,598
Shares, Vested | shares	(146,310)
Unvested as of March 31, 2023 | shares	28,110,693
Weighted Average Grant Date Fair Value, Unvested as of January 1, 2023 | $ / shares	$ 2.30
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.19
Weighted Average Grant Date Fair Value, Vested | $ / shares	3.24
Weighted Average Grant Date Fair Value, Unvested as of March 31, 2023 | $ / shares	$ 2.28

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Weighted Average Assumptions used to Determine Estimated Fair Value of Performance-based Market Condition Share Awards Granted (Details) - Performance-based Market Condition Share Awards [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free rate	4.61%
Term to end of performance period (yrs)	3 years
Valuation date stock price	$ 2.76
Expected volatility	70%
Expected dividend yield	0%

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 20,997	$ 12,085
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	398	335
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,801	2,182
Selling and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	1,986	1,795
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 15,812	$ 7,773

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Pending Litigation [Member]
Loss Contingencies [Line Items]
Pending Claims Number	0	0
Indemnification Agreement [Member]
Loss Contingencies [Line Items]
New Claims Filed, Number	0	0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 1,475	$ (332)

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021
Related Party Transaction [Line Items]
Revenues recognized from related party	$ (29,486)		$ (126,432)
Deferred revenue	73,785		55,794		$ 75,896
Payment to acquire interest in joint venture	980
CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Deferred revenue	931		1,320
Revenues recognized from related party	389	$ 455
Due from related parties	1,602		1,602
Payment to acquire interest in joint venture	980			$ 2,940
Equity method investment, ownership percentage				50%
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Deferred revenue	308		355
Revenues recognized from related party	599	$ 760
Due from related parties	$ 98		$ 995

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net loss	$ (398,509)	$ (70,253)
Net loss attributable to non-controlling interest	(821)	(216)
Net loss attributable to American Well Corporation	$ (397,688)	$ (70,037)
Denominator:
Weighted-average common shares outstanding, basic	279,966,645	268,002,110
Weighted-average common shares outstanding, diluted	279,966,645	268,002,110
Net loss per share attributable to common stockholders, basic	$ (1.42)	$ (0.26)
Net loss per share attributable to common stockholders, diluted	$ (1.42)	$ (0.26)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded From Computation of Earning Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	63,471,567	39,240,578
Unvested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	24,623,215	15,008,289
Unvested performance market-based stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	28,110,693	9,545,814
Options to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	10,737,659	14,686,475